Biotechnology

New patent expiration for Gilead Sciences drug ODEFSEY – DrugPatentWatch


Copyright © DrugPatentWatch. Originally published at the time of expiration of a new patent for the Gilead Sciences drug ODEFSEY


Annual Drug Patent Expiration for ODEFSEY

Odefsey is a drug marketed by Gilead Sciences Inc and included in one NDA. It is available from a single supplier. There are seven patents protecting this drug.

Drug patent litigation for ODEFSEY.

This drug has two hundred and fifty-four patent family members in forty-seven countries.

The generic ingredient in ODEFSEY is emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate. One registered supplier for this compound. Additional details are available on emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published at the time of expiration of a new patent for the Gilead Sciences drug ODEFSEY



Source link

Related Articles

Back to top button